{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:17:06Z","timestamp":1760149026256,"version":"build-2065373602"},"reference-count":78,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>In late 2019, the world was shaken by the COVID-19 pandemic. Severe Acute Respiratory Syndrome Coronavirus\u20142 (SARS-CoV-2) infection became one of the main causes of illness and hospitalization worldwide, especially in subjects with metabolic comorbidities such as obesity, diabetes, or liver disease. This scenario crosses with the metabolic liver disorders\u2019 \u201cpandemic\u201d, caused by the exponential spreading of non-alcoholic fatty liver disease, which is now the most prevalent cause of chronic liver disease (CLD). The aim of this review is to analyze the key factors of the relationship between COVID-19 and the spectrum of fatty liver disorders (FLD), in terms of molecular mechanisms and clinical presentation which can predict a more severe course of the infection. In addition, this review will face the change in management of FLD during pandemics, with a central role of telemedicine, and the role of other interventions in preventing and treating severe infection in these subjects.<\/jats:p>","DOI":"10.3390\/jcm12134316","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:45:11Z","timestamp":1687913111000},"page":"4316","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["COVID-19 and Fatty Liver Disorders"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0460-4122","authenticated-orcid":false,"given":"Maria","family":"Guarino","sequence":"first","affiliation":[{"name":"Diseases of the Liver and Biliary System Unit, Department of Clinical Medicine and Surgery, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0000-1076","authenticated-orcid":false,"given":"Valentina","family":"Cossiga","sequence":"additional","affiliation":[{"name":"Diseases of the Liver and Biliary System Unit, Department of Clinical Medicine and Surgery, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cutolo","sequence":"additional","affiliation":[{"name":"Diseases of the Liver and Biliary System Unit, Department of Clinical Medicine and Surgery, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Attanasio","sequence":"additional","affiliation":[{"name":"Diseases of the Liver and Biliary System Unit, Department of Clinical Medicine and Surgery, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Lieto","sequence":"additional","affiliation":[{"name":"Diseases of the Liver and Biliary System Unit, Department of Clinical Medicine and Surgery, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filomena","family":"Morisco","sequence":"additional","affiliation":[{"name":"Diseases of the Liver and Biliary System Unit, Department of Clinical Medicine and Surgery, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Guarino, M., Cossiga, V., Capasso, M., Mazzarelli, C., Pelizzaro, F., Sacco, R., Russo, F.P., Vitale, A., Trevisani, F., and Cabibbo, G. (2022). Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma. J. Clin. Med., 11.","DOI":"10.3390\/jcm11154475"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.cgh.2022.01.012","article-title":"Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients","volume":"20","author":"Guarino","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Cossiga, V., Capasso, M., Guarino, M., Loperto, I., Brusa, S., Cutolo, F.M., Attanasio, M.R., Lieto, R., Portella, G., and Morisco, F. (2023). Safety and Immunogenicity of Anti-SARS-CoV-2 Booster Dose in Patients with Chronic Liver Disease. J. Clin. Med., 12.","DOI":"10.3390\/jcm12062281"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2016). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.2012.39","article-title":"Prevalence of obesity and trends in the distribution of body mass Index Among US Adults, 1999\u20132010","volume":"307","author":"Flegal","year":"2012","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cgh.2011.03.020","article-title":"Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008","volume":"9","author":"Younossi","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the Global Burden of Chronic Liver Diseases from 2012 to 2017: The Growing Impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MD.0b013e3182779d49","article-title":"Nonalcoholic fatty liver disease in lean individuals in the United States","volume":"91","author":"Younossi","year":"2012","journal-title":"Medicine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/liv.12619","article-title":"High prevalence of non-alcoholic fatty liver disease in the Chinese\u2014Results from the Hong Kong liver health census","volume":"35","author":"Fung","year":"2015","journal-title":"Liver Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1665-2681(19)31559-5","article-title":"Non-alcoholic fatty liver disease and the metabolic syndrome in an urban hospital serving an African community","volume":"10","author":"Onyekwere","year":"2011","journal-title":"Ann. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Gonz\u00e1lez, \u00c1.A., Altisench Jan\u00e9, B., Masmiquel Comas, L., Arroyo Bote, S., Gonz\u00e1lez San Miguel, H.M., and Ram\u00edrez Manent, J.I. (2022). Impact of COVID-19 Lockdown on Non-Alcoholic Fatty Liver Disease and Insulin Resistance in Adults: A before and after Pandemic Lockdown Longitudinal Study. Nutrients, 14.","DOI":"10.3390\/nu14142795"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/liv.15158","article-title":"Lifestyle changes during the coronavirus disease 2019 pandemic impact metabolic dysfunction-associated fatty liver disease","volume":"42","author":"Fujii","year":"2022","journal-title":"Liver Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/oby.23728","article-title":"Rising NAFLD and Metabolic Severity during the SARS-CoV-2 Pandemic among Children with Obesity in the United States","volume":"31","author":"Slusher","year":"2023","journal-title":"Obesity"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Montemayor, S., Mascar\u00f3, C.M., Ugarriza, L., Casares, M., G\u00f3mez, C., Mart\u00ednez, J.A., Tur, J.A., and Bouzas, C. (2022). Intrahepatic Fat Content and COVID-19 Lockdown in Adults with NAFLD and Metabolic Syndrome. Nutrients, 14.","DOI":"10.3390\/nu14173462"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Cinque, F., Cespiati, A., Lombardi, R., Costantino, A., Maffi, G., Alletto, F., Colavolpe, L., Francione, P., Oberti, G., and Fatta, E. (2022). Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown. Nutrients, 14.","DOI":"10.3390\/nu14030556"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e13597","DOI":"10.1111\/eci.13597","article-title":"Multiplying effects of COVID-19 lockdown on metabolic risk and fatty liver","volume":"51","author":"Shanmugam","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100574","DOI":"10.1016\/j.jhepr.2022.100574","article-title":"Impact of the COVID-19 pandemic on the care and outcomes of people with NAFLD-related cirrhosis","volume":"4","author":"Broquetas","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e000794","DOI":"10.1136\/bmjgast-2021-000794","article-title":"COVID-19 and liver cancer: Lost patients and larger tumours","volume":"9","author":"Geh","year":"2022","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100057","DOI":"10.1016\/j.metop.2020.100057","article-title":"The incidence of COVID-19 in patients with metabolic syndrome and non-alcoholic steatohepatitis: A population-based study","volume":"8","author":"Ghoneim","year":"2020","journal-title":"Metabol. Open."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"11212","DOI":"10.1111\/jcmm.17042","article-title":"Association between non-alcoholic fatty liver disease with the susceptibility and outcome of COVID-19: A retrospective study","volume":"25","author":"Wang","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.3346\/jkms.2021.36.e291","article-title":"Non-alcoholic Fatty Liver Disease and COVID-19 Susceptibility and Outcomes: A Korean Nationwide Cohort","volume":"36","author":"Yoo","year":"2021","journal-title":"J. Korean Med. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Rosso, C., Demelas, C., Agostini, G., Abate, M.L., Vernero, M., Caviglia, G.P., D\u2019Amato, D., Armandi, A., Tapparo, M., and Guariglia, M. (2022). Expression of SARS-Cov-2 Entry Factors in Patients with Chronic Hepatitis. Viruses, 14.","DOI":"10.3390\/v14112397"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"104219","DOI":"10.1016\/j.compbiomed.2021.104219","article-title":"A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection?","volume":"130","author":"Singh","year":"2021","journal-title":"Comput. Biol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jhep.2020.03.044","article-title":"Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study","volume":"73","author":"Ji","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Calapod, O.P., Marin, A.M., Onisai, M., Tribus, L.C., Pop, C.S., and Fierbinteanu-Braticevici, C. (2021). The Impact of Increased Fib-4 Score in Patients with Type II Diabetes Mellitus on COVID-19 Disease Prognosis. Medicina, 57.","DOI":"10.3390\/medicina57050434"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jhep.2020.09.006","article-title":"NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression\u2014The debate continues","volume":"74","author":"Mushtaq","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/hep4.1592","article-title":"Clinical Features of Patients with COVID-19 with Nonalcoholic Fatty Liver Disease","volume":"4","author":"Huang","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1007\/s10620-020-06618-3","article-title":"Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19","volume":"66","author":"Chen","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"ofac073","DOI":"10.1093\/ofid\/ofac073","article-title":"Association of Nonalcoholic Fatty Liver Disease With COVID-19 Severity and Pulmonary Thrombosis: CovidFAT, a Prospective, Observational Cohort Study","volume":"9","author":"Vrsaljko","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Chai, X., Hu, L., Zhang, Y., Han, W., Lu, Z., Ke, A., Zhou, J., Shi, G., Fang, N., and Fan, J. (2020). Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. bioRxiv.","DOI":"10.1101\/2020.02.03.931766"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101894","DOI":"10.1016\/j.clinre.2022.101894","article-title":"Abnormal liver tests and non-alcoholic fatty liver disease predict disease progression and outcome of patients with COVID-19","volume":"46","author":"Tripon","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gjura\u0161in, B., Jeli\u010di\u0107, M., Kutle\u0161a, M., and Papi\u0107, N. (2022). The Impact of Nonalcoholic Fatty Liver Disease on Severe Community-Acquired Pneumonia Outcomes. Life, 13.","DOI":"10.3390\/life13010036"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Halim, C., Mirza, A.F., and Sari, M.I. (2022). The Association between TNF-\u03b1, IL-6, and Vitamin D Levels and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis. Pathogens, 11.","DOI":"10.3390\/pathogens11020195"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Papic, N., Samadan, L., Vrsaljko, N., Radmanic, L., Jelicic, K., Simicic, P., Svoboda, P., Lepej, S.Z., and Vince, A. (2022). Distinct Cytokine Profiles in Severe COVID-19 and Non-Alcoholic Fatty Liver Disease. Life, 12.","DOI":"10.3390\/life12060795"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"899930","DOI":"10.3389\/fimmu.2022.899930","article-title":"High Number and Specific Comorbidities Could Impact the Immune Response in COVID-19 Patients","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"604100","DOI":"10.3389\/fendo.2021.604100","article-title":"Association and Interaction between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients with Severe Coronavirus Disease 2019","volume":"12","author":"Gao","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jhep.2022.07.028","article-title":"Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States","volume":"78","author":"Gao","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/hep4.1957","article-title":"Interaction of metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients hospitalized with coronavirus disease 2019","volume":"6","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1111\/liv.14575","article-title":"Metabolic-associated fatty liver disease is associated with severity of COVID-19","volume":"40","author":"Zhou","year":"2020","journal-title":"Liver Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/MEG.0000000000001902","article-title":"Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: A retrospective case-control study","volume":"33","author":"Mahamid","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.soard.2021.05.029","article-title":"Metabolic surgery may protect against admission for COVID-19 in persons with nonalcoholic fatty liver disease","volume":"17","author":"Tignanelli","year":"2021","journal-title":"Surg. Obes. Relat. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Forlano, R., Mullish, B.H., Mukherjee, S.K., Nathwani, R., Harlow, C., Crook, P., Judge, R., Soubieres, A., Middleton, P., and Daunt, A. (2020). In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0240400"},{"key":"ref_46","first-page":"e26683","article-title":"Effect of Nonalcoholic Fatty Liver Disease (NAFLD) on COVID-19: A Single-Center Study of 3983 Patients with Review of Literature","volume":"14","author":"Nath","year":"2022","journal-title":"Cureus"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"100271","DOI":"10.1016\/j.aohep.2020.09.015","article-title":"Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19)","volume":"20","author":"Gall","year":"2021","journal-title":"Ann. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cgh.2022.01.045","article-title":"Mendelian Randomization Analysis Reveals No Causal Relationship between Nonalcoholic Fatty Liver Disease and Severe COVID-19","volume":"20","author":"Li","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI45887","article-title":"Adipose tissue remodeling and obesity","volume":"121","author":"Sun","year":"2011","journal-title":"J. Clin. Invest."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.3748\/wjg.v28.i37.5444","article-title":"Prognostic performance of an index based on lactic dehydrogenase and transaminases for patients with liver steatosis and COVID-19","volume":"28","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Crudele, L., Novielli, F., Petruzzelli, S., Battaglia, S., Giuliano, A.F.M., Melodia, R., Morano, C.M., Dell\u2019Aquila, P., Moretti, R., and Castorani, L. (2022). Liver Fibrosis Indices Predict the Severity of SARS-CoV-2 Infection. J. Clin. Med., 11.","DOI":"10.3390\/jcm11185369"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jceh.2022.04.013","article-title":"Is Fatty Liver Associated with Increased Mortality and Morbidity in Coronavirus Disease 2019 (COVID-19) Pneumonia?","volume":"12","author":"Madan","year":"2022","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3803\/EnM.2021.1040","article-title":"High Fibrosis-4 Index Is Related with Worse Clinical Outcome in Patients with Coronavirus Disease 2019 and Diabetes Mellitus: A Multicenter Observational Study","volume":"36","author":"Kim","year":"2021","journal-title":"Endocrinol. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1007\/s10620-021-07120-0","article-title":"Impact of Fibrosis-4 Index Prior to COVID-19 on Outcomes in Patients at Risk of Non-alcoholic Fatty Liver Disease","volume":"67","author":"Elfeki","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e23880","DOI":"10.1002\/jcla.23880","article-title":"Risk of severe illness of COVID-19 patients with NAFLD and increased NAFLD fibrosis scores","volume":"35","author":"Yao","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2020.06.001","article-title":"High rates of 30-day mortality in patients with cirrhosis and COVID-19","volume":"73","author":"Iavarone","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_58","unstructured":"OMS (2023, January 27). WHO Coronavirus (COVID-19) Dashboard. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Bhimraj, A., Morgan, R.L., Shumaker, A.H., Baden, L., Cheng, V.C.C., Edwards, K.M., Gallagher, J.C., Gandhi, R.T., Muller, W.J., and Nakamura, M.M. (2022). Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin. Infect. Dis., ciac724.","DOI":"10.1093\/cid\/ciac724"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1111\/bcp.14831","article-title":"Liver and kidney function in patients with COVID-19 treated with remdesivir","volume":"87","author":"Guchelaar","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s12072-020-10077-3","article-title":"Liver injury in remdesivir-treated COVID-19 patients","volume":"14","author":"Zampino","year":"2020","journal-title":"Hepatol. Int."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/phar.2464","article-title":"Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series","volume":"40","author":"Carothers","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_63","first-page":"e34221","article-title":"Remdesivir-Associated Acute Liver Failure in a COVID-19 Patient: A Case Report and Literature Review","volume":"15","author":"Matar","year":"2023","journal-title":"Cureus"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e00866","DOI":"10.14309\/crj.0000000000000866","article-title":"Acute Liver Failure Secondary to Remdesivir in the Treatment of COVID-19","volume":"9","author":"Lin","year":"2022","journal-title":"ACG Case Rep. J."},{"key":"ref_65","unstructured":"(2023, May 10). LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. 2012, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547852\/."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.ajpath.2012.12.033","article-title":"A unifying ontology to integrate histological and clinical observations for drug-induced liver injury","volume":"182","author":"Wang","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_67","unstructured":"(2023, April 08). Businesswire. Available online: https:\/\/www.businesswire.com\/news\/home\/20200420005795\/en\/University-Hospitals-Expands-Use-of-TempTraq%C2%AE-System-Wide-to-Support-Frontline-Care-Workers-in-the-Fight-Against-COVID-19."},{"key":"ref_68","unstructured":"Best, J. (2023, April 08). Apple Watch. Available online: https:\/\/www.zdnet.com\/article\/apple-watch-fitbit-data-can-find-covid-19-infections-days-before-symptoms-show-up\/."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1756284820959183","DOI":"10.1177\/1756284820959183","article-title":"Tocilizumab and liver injury in patients with COVID-19","volume":"13","author":"Serviddio","year":"2020","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1016\/j.dsx.2020.10.001","article-title":"Pattern of liver function and clinical profile in COVID-19: A cross-sectional study of 91 patients","volume":"14","author":"Kumar","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12967-020-02399-5","article-title":"Eating habits and lifestyle changes during COVID-19 lockdown: An Italian survey","volume":"18","author":"Gualtieri","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/ajcn\/nqaa336","article-title":"Diet and physical activity during the coronavirus disease 2019 (COVID-19) lockdown (March\u2013May 2020): Results from the French NutriNet-Sant\u00e9 cohort study","volume":"113","author":"Esseddik","year":"2021","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"104853","DOI":"10.1016\/j.appet.2020.104853","article-title":"Obesity, eating behavior and physical activity during COVID-19 lockdown: A study of UK adults","volume":"156","author":"Robinson","year":"2021","journal-title":"Appetite"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Mascar\u00f3, C.M., Bouzas, C., Montemayor, S., Garc\u00eda, S., Mateos, D., Casares, M., G\u00f3mez, C., Ugarriza, L., Borr\u00e0s, P.A., and Mart\u00ednez, J.A. (2022). Impact of Physical Activity Differences Due to COVID-19 Pandemic Lockdown on Non-Alcoholic Fatty Liver Parameters in Adults with Metabolic Syndrome. Nutrients, 14.","DOI":"10.3390\/nu14122370"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.clnesp.2021.03.031","article-title":"Telemedicine as a tool for dietary intervention in NAFLD-HIV patients during the COVID-19 lockdown: A randomized controlled trial","volume":"43","author":"Policarpo","year":"2021","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e30239","DOI":"10.2196\/30239","article-title":"Utilization of a Directly Supervised Telehealth-Based Exercise Training Program in Patients with Nonalcoholic Steatohepatitis: Feasibility Study","volume":"5","author":"Motz","year":"2021","journal-title":"JMIR Form. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jhep.2021.04.026","article-title":"Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study","volume":"75","author":"Wang","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3350\/cmh.2022.0082","article-title":"Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients","volume":"28","author":"Cheung","year":"2022","journal-title":"Clin. Mol. Hepatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/13\/4316\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:02:01Z","timestamp":1760126521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/13\/4316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":78,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["jcm12134316"],"URL":"https:\/\/doi.org\/10.3390\/jcm12134316","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2023,6,27]]}}}